Elite Journal of Laboratory Medicine. Volume 2 Issue 7(2024), Pp. 30-37
https://epjournals.com/journals/EJLM

# Phospholipid Signaling and Vaso-Occlusive Events in Sickle Cell Disease

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

## Abstract
Sickle cell disease (SCD) is a hereditary hematological disorder characterized by the production of abnormal hemoglobin S (HbS), leading to the sickling of red blood cells (RBCs) and subsequent vaso-occlusive events (VOEs). These acute episodes, marked by severe pain and ischemia, significantly affect patients' quality of life. Recent studies have identified phospholipid signaling as a crucial contributor to the pathophysiology of SCD, influencing various processes such as inflammation, endothelial dysfunction, and platelet activation. Phospholipids, including lysophosphatidic acid (LPA), phosphatidic acid (PA), and sphingosine-1-phosphate (S1P), serve as key mediators that modulate cellular responses involved in VOEs. The dysregulation of phospholipid metabolism can lead to enhanced inflammatory responses and altered endothelial function, promoting the adhesion of sickled RBCs and leukocytes to the vascular endothelium. This process contributes to the microvascular occlusion characteristic of vaso-occlusive crises. Elevated levels of phospholipid mediators have been associated with increased pain severity and frequency of VOEs, suggesting a direct link between phospholipid signaling and disease exacerbation in SCD.

***Keywords****: sickle cell disease, vaso-occlusive events, phospholipid signaling, inflammation, endothelial dysfunction, platelet activation.*

## Introduction
Sickle cell disease (SCD) is a genetic hematological disorder characterized by the presence of abnormal hemoglobin S (HbS) resulting from a mutation in the β-globin gene. The pathological hallmark of SCD is the polymerization of HbS under low oxygen conditions, which leads to the distortion of red blood cells (RBCs) into a rigid, sickle shape. This morphological change disrupts normal blood flow and contributes to a variety of complications, particularly vaso-occlusive events (VOEs), which are characterized by acute pain and tissue ischemia. VOEs represent one of the most significant clinical manifestations of SCD, leading to frequent hospitalizations and a considerable reduction in the quality of life for affected individuals.[1-5] The pathophysiology of vaso-occlusive crises in SCD is multifactorial, involving a complex interplay of genetic, hematological, and environmental factors. One of the critical elements in the exacerbation of VOEs is the inflammatory response. Chronic inflammation in SCD results from the activation of various immune cells and the release of pro-inflammatory mediators, leading to endothelial dysfunction and increased adhesion of sickled RBCs and leukocytes to the vascular endothelium. This process plays a pivotal role in promoting microvascular obstruction, contributing to the ischemic damage and pain associated with VOEs.[6-10]

**Citation**: Obeagu EI. Phospholipid Signaling and Vaso-Occlusive Events in Sickle Cell Disease. Elite Journal of Laboratory Medicine, 2024; 2(7): 30-37

Recent studies have highlighted the significance of phospholipid signaling in the pathogenesis of SCD and its role in mediating the inflammatory response associated with VOEs. Phospholipids are essential components of cellular membranes, serving not only as structural components but also as bioactive signaling molecules that regulate various physiological processes. In SCD, alterations in phospholipid metabolism can lead to the release of specific lipid mediators, such as lysophosphatidic acid (LPA), phosphatidic acid (PA), and sphingosine-1-phosphate (S1P), which have been implicated in promoting inflammation, endothelial dysfunction, and platelet activation. Lysophosphatidic acid (LPA) is one of the most studied phospholipid mediators in the context of SCD. Elevated levels of LPA have been associated with increased inflammatory responses and endothelial activation, leading to the expression of adhesion molecules and enhanced leukocyte recruitment to sites of vascular obstruction. This process exacerbates the risk of microvascular occlusion, contributing to the frequency and severity of vaso-occlusive crises in patients with SCD. Furthermore, LPA's ability to activate platelets and promote their aggregation adds another layer of complexity to the pathophysiological mechanisms underlying VOEs.[11-15]

Phosphatidic acid (PA) also plays a significant role in the signaling pathways involved in SCD. PA, generated from the hydrolysis of membrane phospholipids, acts as a second messenger in various signaling cascades. In the context of VOEs, PA can enhance endothelial cell activation, leading to increased expression of adhesion molecules and the promotion of leukocyte adhesion to the endothelium. This interaction further exacerbates the inflammatory response and contributes to the occurrence of vaso-occlusive events.[16-20] Sphingosine-1-phosphate (S1P) is another critical phospholipid mediator that influences endothelial function and vascular integrity. S1P, produced from sphingomyelin, regulates various processes, including vascular permeability, immune cell trafficking, and inflammation. In SCD, dysregulation of S1P signaling can lead to increased endothelial permeability and promote the adhesion of sickled RBCs and leukocytes, further contributing to the risk of VOEs. Understanding the role of S1P in SCD provides valuable insights into the mechanisms that underlie endothelial dysfunction and inflammation in this condition.[21-25]

Phospholipid signaling not only affects inflammation and endothelial function but also has implications for platelet activation and thrombotic complications in SCD. The exposure of phosphatidylserine (PS) on activated platelets creates a procoagulant environment, promoting thrombin generation and fibrin formation. This activation of the coagulation cascade, coupled with the presence of sickled RBCs, increases the likelihood of thrombus formation and further aggravates the risk of vaso-occlusive events.[26-30] Given the pivotal role of phospholipid signaling in mediating the inflammatory response and contributing to the pathophysiology of vaso-occlusive crises, targeting these pathways may offer therapeutic opportunities for managing sickle cell disease. Therapeutic strategies aimed at modulating phospholipid metabolism or inhibiting specific signaling pathways could help alleviate the severity of VOEs and improve patient outcomes.[31-35]

**Mechanisms of Phospholipid Signaling in Vaso-Occlusive Events**

In sickle cell disease (SCD), the sickling of red blood cells (RBCs) leads to membrane damage and the release of various phospholipids into the circulation. This release alters the balance of bioactive lipid mediators in the body, leading to significant pathophysiological consequences. The metabolism of phospholipids, such as phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin, results in the production of bioactive lipid mediators, including lysophosphatidic acid (LPA), phosphatidic acid (PA), and sphingosine-1-phosphate (S1P). These lipid mediators

can activate various signaling pathways, contributing to inflammation, endothelial dysfunction, and the activation of coagulation pathways that are crucial in the context of vaso-occlusive events (VOEs).[36-40] Lysophosphatidic acid (LPA) is a potent bioactive lipid that plays a significant role in promoting inflammation and vascular responses in SCD. LPA is produced from the enzymatic action of lysophospholipase D on phosphatidic acid and acts through specific G protein-coupled receptors (GPCRs) to mediate its effects. In SCD, elevated levels of LPA have been associated with increased expression of adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), on endothelial cells. This enhanced expression promotes the adhesion of sickled RBCs and leukocytes to the endothelium, facilitating the obstruction of small blood vessels and contributing to the occurrence of vaso-occlusive events.[41-45]

Phosphatidic acid (PA) acts as a second messenger in various signaling pathways and has been implicated in promoting endothelial activation and inflammation. PA can activate the mechanistic target of rapamycin (mTOR) signaling pathway, which regulates cell growth, proliferation, and inflammatory responses. In the context of SCD, the production of PA from membrane phospholipids can lead to increased activation of endothelial cells, resulting in enhanced expression of adhesion molecules and the promotion of leukocyte recruitment. This process amplifies the inflammatory response and exacerbates the risk of microvascular occlusion, contributing to the severity of vaso-occlusive events.[46-50] Sphingosine-1-phosphate (S1P) is another critical phospholipid mediator that plays a role in vascular homeostasis and immune regulation. In SCD, S1P is produced from sphingomyelin through the action of sphingomyelinase and sphingosine kinase. S1P exerts its effects by binding to specific S1P receptors (S1PRs) on endothelial cells, leukocytes, and platelets. In healthy individuals, S1P helps maintain vascular integrity and regulates leukocyte trafficking; however, in SCD, dysregulation of S1P signaling can lead to increased endothelial permeability and enhanced adhesion of sickled RBCs and leukocytes to the endothelium. This dysregulation contributes to the risk of vaso-occlusive events by facilitating the obstruction of blood flow in the microvasculature.[51-55] Phospholipid signaling plays a significant role in the promotion of inflammation in SCD. The release of phospholipid mediators during vaso-occlusive events can activate various immune cells, including neutrophils and macrophages, leading to the release of pro-inflammatory cytokines and chemokines. This inflammatory milieu can enhance the recruitment of additional leukocytes to sites of vascular obstruction, promoting the formation of inflammatory plaques and increasing the likelihood of microvascular occlusion. The interplay between phospholipid signaling and inflammation underscores the importance of targeting these pathways to mitigate the inflammatory response in SCD.[56-60]

Phospholipid signaling directly affects endothelial function, contributing to endothelial dysfunction and increased vascular permeability in SCD. Phospholipid mediators, such as LPA and S1P, can modulate the expression of tight junction proteins and adhesion molecules, leading to increased permeability of the endothelium. In SCD, the presence of sickled RBCs and the release of inflammatory mediators can further exacerbate endothelial dysfunction, creating a vicious cycle that promotes vaso-occlusive events. Understanding the mechanisms underlying endothelial dysfunction in SCD is essential for developing targeted therapies to improve vascular health.[61-63]

Phospholipid signaling significantly impacts platelet activation and thrombus formation in SCD. Phosphatidylserine exposure on activated platelets provides a procoagulant surface, promoting

thrombin generation and fibrin formation. In SCD, sickled RBCs can activate platelets, leading to their aggregation and increased thrombotic risk. Elevated levels of phospholipid mediators, such as LPA, can further enhance platelet reactivity and promote the formation of thrombi, exacerbating the risk of vaso-occlusive events. Targeting phospholipid signaling pathways may provide therapeutic opportunities to modulate platelet activation and reduce thrombotic complications in SCD.[64-66] Phospholipid signaling in SCD does not occur in isolation; it interacts with other signaling pathways, including those mediated by oxidative stress and the complement system. Increased oxidative stress in SCD can lead to the oxidation of phospholipids, generating reactive lipid species that can activate inflammatory pathways. Additionally, complement activation can further enhance phospholipid signaling, creating a feedback loop that perpetuates inflammation and endothelial dysfunction.[67] Given the pivotal role of phospholipid signaling in the pathogenesis of vaso-occlusive events, targeting these pathways may offer promising therapeutic strategies for managing SCD. Approaches to modulate phospholipid metabolism, inhibit specific signaling pathways, or block the actions of bioactive phospholipid mediators could help alleviate the severity of VOEs and improve patient outcomes. For example, pharmacological agents that block LPA receptors or inhibit S1P signaling may help reduce inflammation and endothelial activation, potentially decreasing the frequency and severity of vaso-occlusive crises.[68-69]

## Conclusion

Phospholipid signaling plays a crucial role in the pathogenesis of vaso-occlusive events in sickle cell disease (SCD). The dysregulation of phospholipid metabolism leads to the accumulation of bioactive mediators, such as lysophosphatidic acid (LPA), phosphatidic acid (PA), and sphingosine-1-phosphate (S1P), which contribute to inflammation, endothelial dysfunction, and platelet activation. These processes are intricately linked to the development and exacerbation of vaso-occlusive crises, resulting in significant morbidity for affected individuals. Approaches aimed at modulating phospholipid metabolism or inhibiting specific signaling pathways hold promise for alleviating the severity of vaso-occlusive events and improving patient outcomes in SCD. As research continues to uncover the complex interactions between phospholipids and other signaling pathways, there is potential for innovative treatments that can address the multifactorial nature of this disease.

## References

1. Alenzi FQ, AlShaya DS. Biochemical and molecular analysis of the beta-globin gene on Saudi sickle cell anemia. Saudi Journal of Biological Sciences. 2019;26(7):1377-1384.
2. Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annual review of genomics and human genetics. 2018;19(1):113-147.
3. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
4. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
5. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
6. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.

7. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
8. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-158.
9. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
10. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
11. Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circulation research. 2007 Sep 28;101(7):654-662.
12. Tran N, Garcia T, Aniqa M, Ali S, Ally A, Nauli SM. Endothelial nitric oxide synthase (eNOS) and the cardiovascular system: in physiology and in disease states. American journal of biomedical science & research. 2022;15(2):153.
13. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
14. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
15. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
16. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
17. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
18. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
19. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
20. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
21. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
22. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
23. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
24. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).

25. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology. 2024;2(3):67-80.
26. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
27. Vilas-Boas W, Cerqueira BA, Zanette AM, Reis MG, Barral-Netto M, Goncalves MS. Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Annals of hematology. 2010; 89:877-882.
28. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-265.
29. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
30. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
31. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
32. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
33. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
34. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
35. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
36. Tsikas D. Does the inhibitory action of asymmetric dimethylarginine (ADMA) on the endothelial nitric oxide synthase activity explain its importance in the cardiovascular system? The ADMA paradox. Journal of Controversies in Biomedical Research. 2017;3(1):16-22.
37. Martins R, Knapp S. Heme and hemolysis in innate immunity: adding insult to injury. Current opinion in immunology. 2018; 50:14-20.
38. Wu G, Meininger CJ, McNeal CJ, Bazer FW, Rhoads JM. Role of L-arginine in nitric oxide synthesis and health in humans. Amino acids in nutrition and health: Amino acids in gene expression, metabolic regulation, and exercising performance. 2021:167-87.
39. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at

Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
40. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
41. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
42. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.
43. Roberts BW, Mitchell J, Kilgannon JH, Chansky ME, Trzeciak S. Nitric oxide donor agents for the treatment of ischemia/reperfusion injury in human subjects: a systematic review. Shock. 2013;39(3):229-339.
44. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
45. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024 Feb 9;103(6):e37127.
46. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
47. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
48. Samidurai A, Xi L, Das A, Kukreja RC. Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders. Annual review of pharmacology and toxicology. 2023;63(1):585-615.
49. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024;103(2):e36898.
50. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
51. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
52. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
53. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
54. Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, Golab J. Myeloid cell-derived arginase in cancer immune response. Frontiers in immunology. 2020; 11:938.
55. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
56. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.

57. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:67-80.
58. Obeagu EI, Obeagu GU. Overcoming Hurdles: Anemia Management in Malaria-Affected Childhood. Elite Journal of Laboratory Medicine. 2024;2(1):59-69.
59. Bontempo P, Capasso L, De Masi L, Nebbioso A, Rigano D. Therapeutic Potential of Natural Compounds Acting through Epigenetic Mechanisms in Cardiovascular Diseases: Current Findings and Future Directions. Nutrients. 2024;16(15):2399.
60. Cao M, Zhao Y, He H, Yue R, Pan L, Hu H, Ren Y, Qin Q, Yi X, Yin T, Ma L. New applications of HBOC-201: a 25-year review of the literature. Frontiers in Medicine. 2021; 8:794561.
61. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. The Pharmacogenomics Journal. 2003;3(4):215-226.
62. Obeagu EI. Redox Signaling and Vaso-Occlusive Crisis in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 26-35
63. Obeagu EI. Hypoxia-Induced Signaling in the Pathogenesis of Vaso-Occlusive Crisis. *Elite Journal of Haematology, 2024; 2(7):* 36-43
64. Obeagu EI. Neurovascular Regulation and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 41-48
65. Obeagu EI. Bone Marrow Microenvironment and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 49-56
66. Obeagu EI. Role of G6PD Deficiency in Vaso-Occlusive Phenomena in Sickle Cell Disease. Elite Journal of Medical Sciences, 2024; 2(7):49-57
67. Obeagu EI. Role of the Reticuloendothelial System in Sickle Cell Vaso-Occlusion. Elite Journal of Medical Sciences, 2024; 2(7):58-65
**68.** Obeagu EI. Role of Myeloid-Derived Suppressor Cells in Vaso-Occlusive Crisis. Elite Journal of Health Science, 2024; 2(7): 28-35
**69.** Obeagu EI. Complement System Activation in Vaso-Occlusive Crisis of Sickle Cell Anemia. Elite Journal of Health Science, 2024; 2(7): 36-43